WallStSmart
IOVA

Iovance Biotherapeutics Inc

NASDAQ: IOVA · HEALTHCARE · BIOTECHNOLOGY

$3.36
+1.51% today

Updated 2026-04-30

Market cap
$1.41B
P/E ratio
P/S ratio
5.36x
EPS (TTM)
$-1.09
Dividend yield
52W range
$2 – $6
Volume
17.4M

WallStSmart proprietary scores

32
out of 100
Grade: F
Strong Sell
Investment rating
5.7
Growth
C+
5.0
Quality
C+
2.0
Profitability
F
5.3
Valuation
C+
/9
Piotroski F-Score
Altman Z-Score
Industry rank
View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target
$9.00
+167.86%
12-Month target
Intrinsic (DCF)
$2.74
Margin of safety
+5.11%
2 Strong Buy6 Buy3 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
+ Revenue growth 17.70% QoQ
Risks
- Thin margins at -148.40%
- Negative free cash flow $-61.88M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$238000.00$1.19M$164.07M$263.50M$263.50M
Net income$-389.92M$-444.04M$-372.18M$-390.98M$-71.90M
EPS$-1.09
Free cash flow$-313.18M$-384.11M$-364.05M$-336.24M$-61.88M
Profit margin-163,833.19%-37,345.42%-226.84%-148.38%-148.40%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
IOVA$1.41B325.72.05.35.0+5.11%Avoid
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$336.47B545.35.57.34.8+42.09%Buy
AZN$287.11B646.78.05.35.0+4.07%Buy

Smart narrative

Iovance Biotherapeutics Inc trades at $3.36. Our Smart Value Score of 32/100 indicates the stock is weak. TTM revenue stands at $263.50M. with profit margins at -148.40%. Our DCF model estimates intrinsic value at $2.74.

Frequently asked questions

What is Iovance Biotherapeutics Inc's stock price?
Iovance Biotherapeutics Inc (IOVA) trades at $3.36.
Is Iovance Biotherapeutics Inc overvalued?
Smart Value Score 32/100 (Grade F, Strong Sell). DCF value $2.74.
What is the price target of Iovance Biotherapeutics Inc (IOVA)?
The analyst target price is $9.00, representing +167.9% upside from the current price of $3.36.
What is the intrinsic value of Iovance Biotherapeutics Inc (IOVA)?
Based on our DCF model, intrinsic value is $2.74, a +5.1% margin of safety versus $3.36.
What is Iovance Biotherapeutics Inc's revenue?
TTM revenue is $263.50M.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio5.36x
ROE-55.50%
Beta0.76
50D MA$3.71
200D MA$2.73
Shares out0.41B
Float0.35B
Short ratio
Avg volume17.4M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years